capecitabine and irinotecan for maintenance in colon cancer – pro
The Xeliri combination is well-established for the treatment of colorectal cancer, but there is limited data on its use for maintenance. Sobol reviewed 12 maintenance trials. Ten trials used oxaliplatin with either capecitabine (CapeOx) or fluorouracil and leucovorin (FOLFOX) as part of the induction regimen, and 2 used irinotecan-based therapy. Only the oxaliplatin including trials showed a PFS benefit. Teh authors concluded that for patients with mCRC who achieve at least stable disease after a specified period of induction regimen (3-4 months), a maintenance strategy with at least FP with or without the addition of Bev is preferred.
M. B. Sonbol et al, The Role of Maintenance Strategies in Metastatic Colorectal Cancer
A Systematic Review and Network Meta-analysis of Randomized Clinical Trials. AMA Oncol. 2020;6(3):e194489. doi:10.1001/jamaoncol.2019.4489.
Auber M, L, Wen S, Hobbs G, Higa G, M: Capecitabine as Maintenance Therapy for High-Risk, Resected Colorectal Cancer. Gastrointest Tumors 2021;8:81-86. doi: 10.1159/000513960
Xu, RH., Shen, L., Li, J. et al. Expert consensus on maintenance treatment for metastatic colorectal cancer in China. Chin J Cancer 35, 13 (2016). https://doi.org/10.1186/s40880-015-0067-x